Leslie Lu 의 보수는 EC Healthcare 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-HK$12m
Jun 30 2024	n/a	n/a	-HK$15m
Mar 31 2024	HK$5m	HK$5m	-HK$19m
Dec 31 2023	n/a	n/a	-HK$11m
Sep 30 2023	n/a	n/a	-HK$4m
Jun 30 2023	n/a	n/a	HK$33m
Mar 31 2023	HK$21m	HK$4m	HK$70m
Dec 31 2022	n/a	n/a	HK$93m
Sep 30 2022	n/a	n/a	HK$117m
Jun 30 2022	n/a	n/a	HK$157m
Mar 31 2022	HK$13m	HK$2m	HK$198m

보상 대 시장: Leslie 의 총 보상 ($USD 620.12K )은 Hong Kong 시장( $USD 230.70K ).

보상과 수익: Leslie 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Leslie Lu (44 yo)

1.1yrs

테뉴어

HK$4,818,000

보상

Mr. Lyn Wade Lu, also known as Leslie, served as Co-Chief Executive Officer & Executive Director at EC Healthcare since August 23, 2021 until November 1, 2023. He serves as Chief Executive Officer at EC He...

리더십 팀

이름	위치	테뉴어	보상	소유권
Chi Fai Tang	Founder & Executive Chairman	9.1yrs	HK$1.24m	60.93% HK$ 483.9m
Lyn Wade Lu	Chief Executive Officer & Executive Director	1.1yrs	HK$4.82m	데이터 없음
Heung Wing Lee	CFO & Executive Director	5.4yrs	HK$3.77m	0.057% HK$ 456.0k
Tai Cheung Wong	Chief Operating Officer	2.4yrs	데이터 없음	데이터 없음
Kelly Tsang	Associate Director of Accounting	no data	데이터 없음	데이터 없음
Kin Keung Chan	Chief Public Affairs Officer & Chief Dental Officer	2.4yrs	데이터 없음	데이터 없음
Katy Ip	Sales Director	no data	데이터 없음	데이터 없음
Chun Pu Chu	Chief Business Officer	4.3yrs	데이터 없음	데이터 없음
Chun Yu Chan	Chief Talent Officer	2.4yrs	데이터 없음	데이터 없음
Julie Chow	Chief Proposition Officer of Healthcare	1.9yrs	데이터 없음	데이터 없음
Chun Pong Siu	Company Secretary	7.3yrs	데이터 없음	데이터 없음

2.4yrs

평균 재임 기간

45yo

평균 연령

경험이 풍부한 관리: 2138 의 관리팀은 경험 ( 2.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Chi Fai Tang	Founder & Executive Chairman	9.1yrs	HK$1.24m	60.93% HK$ 483.9m
Lyn Wade Lu	Chief Executive Officer & Executive Director	3.3yrs	HK$4.82m	데이터 없음
Heung Wing Lee	CFO & Executive Director	4.9yrs	HK$3.77m	0.057% HK$ 456.0k
Ching Nam Ma	Independent Non-Executive Director	8.8yrs	HK$240.00k	0.025% HK$ 201.0k
Andrew Look	Independent Non-Executive Director	8.8yrs	HK$220.00k	데이터 없음
Kun Shing Luk	Non Executive Director	9.3yrs	HK$126.00k	0.24% HK$ 1.9m
Tsun Au	Independent Non-Executive Director	2.3yrs	HK$120.00k	데이터 없음

8.8yrs

평균 재임 기간

44yo

평균 연령

경험이 풍부한 이사회: 2138 의 이사회는 경험(평균 재직 기간 8.8 년)으로 간주됩니다.

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/23 20:04
장 마감 주가	2024/12/23 00:00
수익	2024/09/30
연간 수익	2024/03/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

EC Healthcare 10 애널리스트 중 1 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Tingting Li	BOCI Research Ltd.
Zhuonan Xu	China International Capital Corporation Limited
null null	China International Capital Corporation Limited

EC Healthcare 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Less than half of directors are independent

EC Healthcare, Annual General Meeting, Aug 23, 2024

EC Healthcare Announces the Resignation of Mr. Wong Chi Cheung as Executive Director and Chief Digital Officer of the Company with Effect from 31 December 2023

EC Healthcare Announces Executive Changes

EC Healthcare, Annual General Meeting, Aug 23, 2023

Less than half of directors are independent

Recent updates

Upcoming dividend of HK$0.01 per share

EC Healthcare (HKG:2138) Shares Fly 29% But Investors Aren't Buying For Growth

Dividend of HK$0.01 announced

First half 2025 earnings released: EPS: HK$0.012 (vs HK$0.006 in 1H 2024)

EC Healthcare Declares Ordinary Interim (Semi-Annual) Dividend for the Six Months Ended 30 September 2024, Payable on 24 January 2025

New minor risk - Market cap size

EC Healthcare (HKG:2138) Will Want To Turn Around Its Return Trends

EC Healthcare to Report First Half, 2025 Results on Nov 28, 2024

Ec Healthcare Provides Sales Expectations for Six Months Ended 30 September 2024

Price target increased by 35% to HK$2.84

Less than half of directors are independent

Little Excitement Around EC Healthcare's (HKG:2138) Revenues As Shares Take 31% Pounding

EC Healthcare Provides Group Earnings Guidance for the Period from 1 April 2024 to 30 June 2024

Full year 2024 earnings: EPS and revenues miss analyst expectations

EC Healthcare (HKG:2138) Might Be Having Difficulty Using Its Capital Effectively

Full year 2024 earnings: EPS and revenues miss analyst expectations

EC Healthcare, Annual General Meeting, Aug 23, 2024

EC Healthcare to Report Fiscal Year 2024 Results on Jun 27, 2024

An undisclosed buyer entered into an agreement to acquire additional 51% stake in Preeminent Medical Centre Limited from EC Healthcare (SEHK:2138) for HKD 80.2 million.

EC Healthcare (HKG:2138) Surges 25% Yet Its Low P/S Is No Reason For Excitement

When Should You Buy EC Healthcare (HKG:2138)?

Is EC Healthcare (HKG:2138) A Risky Investment?

New minor risk - Share price stability

EC Healthcare (SEHK:2138) entered into sale and purchase agreement to acquire 6.49% stake in Pangenia Inc from Sharp Point Consultant Limited for HKD 17.4 million.

Slammed 26% EC Healthcare (HKG:2138) Screens Well Here But There Might Be A Catch

EC Healthcare's (HKG:2138) Dividend Is Being Reduced To HK$0.005

EC Healthcare Announces the Resignation of Mr. Wong Chi Cheung as Executive Director and Chief Digital Officer of the Company with Effect from 31 December 2023

Price target decreased by 15% to HK$5.22

First half 2024 earnings released: EPS: HK$0.006 (vs HK$0.068 in 1H 2023)

Here's What's Concerning About EC Healthcare's (HKG:2138) Returns On Capital

EC Healthcare Declares an Interim Dividend for the Six Months Ended 30 September 2023, Payable on January 19, 2024

Ec Healthcare Provides Earnings Guidance for the Six Months Ended 30 September 2023

EC Healthcare to Report First Half, 2024 Results on Nov 30, 2023

EC Healthcare Announces Executive Changes

At HK$3.13, Is EC Healthcare (HKG:2138) Worth Looking At Closely?

Ec Healthcare Approves Dividend for the Year Ended 31 March 2023, Payment Date Is 18 September 2023

Upcoming dividend of HK$0.042 per share at 2.6% yield

EC Healthcare (HKG:2138) Is Paying Out A Dividend Of HK$0.042

Ec Healthcare Approves Final Dividend for the Year Ended 31 March 2023

Is EC Healthcare (HKG:2138) Using Too Much Debt?

New minor risk - Earnings quality

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

EC Healthcare (HKG:2138) Has Announced A Dividend Of HK$0.042

Consensus EPS estimates fall by 31%

EC Healthcare (HKG:2138) Will Pay A Dividend Of HK$0.042

Price target decreased by 11% to HK$8.03

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

EC Healthcare, Annual General Meeting, Aug 23, 2023

EC Healthcare Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 March 2023

Is There Now An Opportunity In EC Healthcare (HKG:2138)?

EC Healthcare to Report Fiscal Year 2023 Final Results on Jun 23, 2023

Be Wary Of EC Healthcare (HKG:2138) And Its Returns On Capital

Is EC Healthcare (HKG:2138) Potentially Undervalued?

EC Healthcare (HKG:2138) Will Want To Turn Around Its Return Trends

Price target increased to HK$9.33

Price target increased to HK$8.04

Upcoming dividend of HK$0.058 per share

EC Healthcare (HKG:2138) Is Paying Out Less In Dividends Than Last Year

Investor sentiment improved over the past week

Consensus forecasts updated

First half 2023 earnings released

EC Healthcare Announces Interim Dividend for the Six Months Ended 30 September 2022, Payable on 20 January 2023

Price target decreased to HK$8.89

Less than half of directors are independent

EC Healthcare Provides Earnings Guidance for the Six Months Ended 30 September 2022

EC Healthcare to Report Q2, 2023 Results on Nov 24, 2022

Investor sentiment improved over the past week

Is Now An Opportune Moment To Examine EC Healthcare (HKG:2138)?

Price target decreased to HK$10.17